Skip to main content
. Author manuscript; available in PMC: 2019 Jul 29.
Published in final edited form as: Oncogene. 2019 Jan 29;38(18):3355–3370. doi: 10.1038/s41388-018-0650-0

Figure 3. Response to CDK4/6 inhibition in vivo is associated with reduced proliferative index:

Figure 3.

(A) The indicated PDX models were randomized for treatment with vehicle or palbociclib when tumor volume reached ~200 mm3. Tumors were treated for 21 days and tumor volume was monitored. Data shows the mean and standard error of the mean. Greater than n=5 mice were treated for each condition. For all PDX models the effect of palbociclib was significant for reducing tumor size (p<0.01). (B) Tumors from treated mice were stained for Ki67. Representative images are shown (scale bar=100 μm). (C) The average difference in Ki67 from the control and palbociclib treated mice was determined at 21 days and related to the average change in tumor volume. There is a significant relationship between change in Ki67 and response to palbociclib (p<0.05). (D) Increase in cyclin D1 and cyclin E1 levels was observed in palbociclib (PD) treated PDXs. Representative images of immunohistochemical staining are shown (scale bar=100 μm).